Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be ...
Palisade Bio announces successful refinement of patient selection strategies for Ulcerative Colitis (UC) based on PDE4B biomarkers, identifying 70% of adult and 90% of pediatric moderate to severe cases. The company is advancing PALI-2108, an orally administered, colon-specific PDE4 inhibitor, with a Phase 1 clinical trial for UC set to begin before year-end.
Reference News
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be ...
Palisade Bio announces successful refinement of patient selection strategies for Ulcerative Colitis (UC) based on PDE4B biomarkers, identifying 70% of adult and 90% of pediatric moderate to severe cases. The company is advancing PALI-2108, an orally administered, colon-specific PDE4 inhibitor, with a Phase 1 clinical trial for UC set to begin before year-end.